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ABSTRACT
DIS3 is a catalytic subunit of the human exosome complex, containing 
exonucleolytic (RNB) and endonucleolytic (PIN) domains, recently found mutated in 
multiple myeloma (MM), a clinically and genetically heterogeneous form of plasma 
cell (PC) dyscrasia. We analyzed by next-generation sequencing (NGS) the DIS3 PIN 
and RNB domains in purified bone marrow PCs from 164 representative patients, 
including 130 cases with MM, 24 with primary PC leukemia and 10 with secondary 
PC leukemia. DIS3 mutations were found respectively in 18.5%, 25% and 30% of 
cases. Identified variants were predominantly missense mutations localized in the 
RNB domain, and were often detected at low allele frequency. DIS3 mutations were 
preferentially carried by IGH-translocated/nonhyperdiploid patients. Sequential 
analysis at diagnosis and relapse in a subset of cases highlighted some instances 
of increasing DIS3 mutation burden during disease progression. NGS also revealed 
that the majority of DIS3 variants in mutated cases were comparably detectable at 
transcriptional level. Furthermore, gene expression profiling analysis in DIS3-mutated 
patients identified a transcriptional signature suggestive for impaired RNA exosome 
function. In conclusion, these data further support the pathological relevance of DIS3 
mutations in plasma cell dyscrasias and suggest that DIS3 may represent a potential 
tumor suppressor gene in such disorders.
INTRODUCTION
Multiple myeloma (MM) is a fatal malignancy of 
bone marrow (BM) plasma cells (PCs) whose pathogenesis 
is only partially understood. PC dyscrasias show a 
wide clinical presentation ranging from the presumed 
pre-malignant condition of monoclonal gammopathy of 
undetermined significance (MGUS) to smoldering MM 
(SMM), symptomatic MM, and extra-medullary MM or 
plasma cell leukemia (PCL) [1]. PCL can be distinguished 
into primary PCL (pPCL), originating de novo without 
any prior history of MM, or secondary PCL (sPCL), 
arising from a preexisting myeloma tumor that eventually 
progressed to the leukemic phase [2].
At the genetic level, MM is characterized by both 
numerical and structural chromosomal alterations [1] 
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alongside somatic gene mutations, as recently emerged 
from whole genome/exome sequencing analyses [3–6]. 
In fact, the general scenario arising from such studies 
indicated a considerable number of non-synonymous 
variants per patient, few recurrently mutated genes of 
probable pathogenetic significance, and a heterogeneous 
subclonal structure at the time of diagnosis [3–6]. Among 
the recurrently mutated genes with putative pathogenetic 
role, the most frequent were KRAS, NRAS, TP53, BRAF, 
TRAF3, FAM46C and DIS3 [3, 4, 6–8].
The DIS3 gene maps at 13q22.1 and encodes 
the catalytic subunit of the human RNA exosome 
complex, prominently participating to RNA processing 
and turnover [9]. DIS3 catalytic activity is governed 
by the endoribonucleolytic (PIN) and the 3’–5’ 
exoribonucleolyitic (RNB) domains. It is indispensable 
for survival in vertebrates [10]. Somatic mutations and 
altered expression have been reported in several cancer 
types (COSMIC catalogue, Release v71, http://cancer.
sanger.ac.uk/cancergenome/projects/cosmic/) [11, 12]. 
Concerning MM, DIS3 was reported as mutated on 
average in 11% of patients [4, 6, 7, 13]. Some DIS3 
mutations identified in MM showed to interfere with 
its exonucleolytic activity, causing aberrant RNA 
metabolism and slower proliferation rate in HEK293-
derived human cell lines [10]. Furthermore, very recently 
we demonstrated that DIS3 facilitates the maturation of 
the tumor suppressor let-7 miRNAs by reducing in the 
cytoplasm the RNA stability of the pluripotency factor 
LIN28B, an inhibitor of let-7 processing. Through the 
reduction of mature let-7, DIS3 enhances the translation 
of let-7 targets such as MYC and RAS leading to enhanced 
tumorigenesis [14].
Here, we assessed by means of next-generation 
sequencing (NGS) the mutational status of DIS3 gene in 
a large and representative series of patients at different 
stages of plasma cell dyscrasia, and related it with other 
biological and clinical features; furthermore, we analyzed 
for the first time the gene expression pattern characterizing 
DIS3-mutated MM patients.
RESULTS
Assessment of DIS3 mutations in PC dyscrasias
To estimate the frequency of DIS3 mutations in 
different phases of plasma cell dyscrasia, 164 cases 
(including 130 MM, 24 pPCL and 10 sPCL patients) and 
20 human myeloma cell lines (HMCLs) were subjected 
to deep sequencing of the two functional domains of the 
gene, namely PIN and RNB domains.
The median depth of coverage was 245x 
(range: 64–1160x). After exclusion of intronic, 
synonymous and germline variants, deep sequencing of 
DIS3 revealed 32 different coding somatic mutations 
globally targeting 27 genic positions (Table 1). The 
presence of each non-synonymous single nucleotide 
variant (SNV) or indel was validated in an independent 
PCR product, analyzed by conventional sequencing 
whenever the sensitivity of the Sanger method (i.e. about 
10% in our experimental conditions) was consistent 
with the variant allele frequency (VAF), or by an 
additional ultra-deep pyrosequencing run (median depth 
of coverage = 1110x) in case of variants at low allele 
frequency. At DNA level, 29 out of 32 variants (90.6%) 
were SNVs, all resulting in missense mutations but one 
(73355968C > T, M1_V16del), which replaces one base 
within the first coding ATG, thus relocating the translation 
start site 16 codons downstream without altering the 
reading frame. The remaining three variants (9.4%) 
were indels: two involved a single different nucleotide 
causing a frameshift, while the other was a 27bp-deletion 
resulting in an in-frame deletion of nine amino acids 
(L48_A56del). Nonsense mutations were not observed. 
Two of the identified variants were exclusively carried by 
two HMCLs (see below).
As for primary patients, 21 out of 30 mutations 
(70%) affected the RNB domain, while only eight variants 
(8/30, 26.7%) were located in the PIN domain. The 
remaining SNV mapped in a region just downstream of the 
RNB domain. Overall, the most affected residue was the 
arginine at position 780 (R780), replaced by a lysine or by 
a threonine in three and two cases, respectively (Figure 1). 
This is in line with what reported in previous MM 
sequencing studies, where this amino acid position was 
already indicated as the major DIS3 mutational hotspot 
[4, 6, 7, 13]. The arginine at position 780 was found 
involved in RNA binding function [15]. Both R780K 
and R780T substitutions are recurrent in MM patients (of 
our and previously published datasets [6, 7, 13]), and the 
former was demonstrated to cause significant aberrations 
of DIS3 exonucleolytic activity and growth inhibition in 
yeast and human cellular models [10]. The second most 
affected residue in our dataset was the aspartic acid at 
position 488 (D488), involved in magnesium ion binding at 
the active site [15]. This residue was mutated in four cases, 
all carrying the D488N substitution, which also represents 
the globally most frequent variant in our series. Of note, 
D488 represents the second most affected residue in DIS3- 
mutated MM patients when combining the results of the 
previous studies [3, 4, 6, 7, 13]. Interestingly, the adjacent 
conserved aspartic acid at position 487 is equally essential 
for magnesium binding, and when substituted with 
asparagine (D487N) it was reported to completely abolish 
DIS3 exonuclease activity in yeast and human cellular 
models, causing molecular phenotypes comparable to the 
DIS3R780K mutant [10]. Notably, two missense variants 
involving D487 residue were detected in our dataset 
(D487V and D487H, each in one patient). These mutations 
were not previously reported in MM. Other recurrently 
mutated positions in our series were T93, H764, F775, 
R789 and R820, each targeted in two samples by the same 
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Table 1: Summary of DIS3 non-synonymous/indel variants identified by NGS in the present dataset
Variant* AA change
dbSNP 
ID (v142)/ 
COSMIC ID 
(v71)
Previously 
reported  
in MM
Mutated samples (VAF)
73346338C > T D488N COSM158635 [6, 13] KMS27 
(49.7%)
MM-343 
(46.2%)
PCL-041 
(45.7%)
MM-
398 
(3.8%)
MM-
042 
(4.6%)
73336064C > T R780K COSM329311 [4, 6, 7, 13] PCL-019 
(47.7%)
PCL-042 
(45.9%)
MM-281 
(36.8%)
73355093T > C T93A / / PCL-021 
(100%)
MM-213 
(56.6%)
73335837G > A R820W
rs372878316/ 
COSM3469577
/ MM-445 
(98.4%)
MM-207 
(2.1%)
73335930G > A R789W / / MM-335 
(94.2%)
PCL-011 
(91.1%)
73336078A > C F775L / [6] MM-036 
(92.6%)
MM-414 
(4.7%)
73336064C > G R780T / [6] PCL-035 
(45.%)
MM-381 
(16.4%)
73352393A > C V171G / http://www.keatslab.org
KMS26 
(100%)
73336112T > C H764R / / PCL-036 
(97.6%)
73337707G > T A670D / / PCL-001 
(97%)
73355010G > C F120L / / MM-123 
(95.3%)
73355048G > A R108C / / MM-424 
(94.3%)
73355008T > G Y121S / [19] OPM2 
(91.8%)
73355018T > C K118E / / PCL-015 
(90.1%)
73355804_73355830del L48_A56del / / MM-340 
(54.9%)
73355968C > T M1_V16del / / MM-464 
(51%)
73336151G > T A751D / / MM-340 
(45.7%)
73346340T > A D487V / / MM-317 
(40.3%)
73346341C > G D487H / / MM-372 
(35.5%)
73345240G > A S550F / / MM-386 
(35.1%)
(Continued )
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substitution, except for H764 (reported to be involved in 
RNA binding [15]) showing different amino acid changes. 
Notably, the majority of these recurrently altered residues 
represent novel DIS3 mutations in MM. In fact only the 
variant F775L has already been reported in another series 
[6]. The 17 remaining genic positions were found privately 
mutated in our cohort. Some of them have been already 
reported as altered in MM (R108, R467, S550) [6] or in 
other cancer types (R820, COSM3469577); among the 
mutated residues never described before, A751 is involved 
in RNA binding [15]. Similar to other studies [3, 4, 6, 7], 
we did not find any mutation involving the residue 
E665, proposed as mutational hotspot by Weißbach and 
colleagues based on their sequencing results [13].
Notably, four patients carried multiple DIS3 
mutations; only in two of these cases (MM-340 and 
PCL-042) two variants were both at high allele frequency, 
while in the remaining samples only one of the mutations 
was above the detection limit of Sanger method, 
accompanied by other variants at low allele frequency. 
In particular, PCL-042 harbored the variants R780K and 
E626K, both in the RNB domain, in 46% and 33% of 
reads, respectively, and MM-340 carried a nine amino acid 
in-frame deletion in the PIN domain (L48_A56del) and a 
missense substitution in the RNB domain (A751D) in 55% 
and 46% of reads, respectively.
Beyond the aforementioned R780 and D487 
residues, whose importance for the catalytic activity 
of the protein has been functionally proven, a potential 
detrimental effect on DIS3 nucleolytic activity can 
be suggested also for many of the other mutations 
we identified here, on the basis of their recurrence 
(as described above), and/or the high conservation of 
affected amino acid residues, and/or the functional 
predictions returned by different algorithms. In fact, 
from the alignment of human DIS3 protein sequence to 
mouse and yeast paralogs and to E.coli RNases II and 
R sequences, we found that 13 of the 24 genic positions 
targeted by mutations resulting in amino acid substitutions 
or in-frame deletions in our primary patients encoded 
Variant* AA change
dbSNP 
ID (v142)/ 
COSMIC ID 
(v71)
Previously 
reported  
in MM
Mutated samples (VAF)
73342930C > T E626K / / PCL-042 
(33.2%)
73346400C > T R467Q rs201674523/ 
COSM1944518
[6]
MM-263 
(31.1%)
73336113G > A H764Y / / MM-207 
(24.6%)
73346400del R467Qfs*4 / / MM-263 
(5.9%)
73355110T > C N87S / / MM-279 
(2.9%)
73337650C > T R689Q COSM1367629 [6] MM-340 
(2.2%)
73336113G > C H764D / / MM-207 
(1.9%)
73336077T > G T776P / / MM-207 
(0.8%)
73343049_73343050insA A586Vfs*7 / / MM-055 
(0.8%)
73355891T > C D27G / / MM-143 
(0.6%)
73345094T > C H568R / / MM-310 
(0.5%)
73345097T > C N567S / / MM-150 
(0.5%)
*Genomic positions based on hg19.
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amino acid residues conserved in all the analyzed species 
(Supplementary Figure S1). Furthermore, 21 out of the 
26 missense mutations were suggested to be functionally 
relevant according to five different prediction tools 
(Supplementary Table S1).
Regarding DIS3 mutations found in the cell lines, 
three out of the 20 analyzed HMCLs were mutated for this 
gene. In particular, KMS27 carried the aforementioned 
D488N hotspot mutation, while OPM2 and KMS26 cells 
harbored the variants Y121S and V171G, respectively. 
Both these substitutions were located in the PIN domain 
and were absent in primary tumors of both our and other 
series; only the V171G involved a highly conserved 
residue and was suggested to be functionally relevant by 
all the bioinformatics predictors. Our data concerning 
HMCLs are concordant with those reported in the 
MM Cell Line Characterization Project (available at http://
www.keatslab.org/data-repository).
DIS3 mutations in different phases and 
molecular subtypes of PC dyscrasia
DIS3 mutations globally affected 33 patients 
(33/164, 20.1%): specifically, 24 MMs at diagnosis (24/130, 
18.5%), six primary PCLs (6/24, 25%), and three secondary 
PCLs (3/10, 30%). The most relevant molecular features of 
the 33 mutated cases are reported in Supplementary Table S2.
We next asked whether there were any 
relationships with cytogenetic lesions. We observed 
a positive association between DIS3 mutations and 
IGH@ translocations (P value = 0.0046), particularly 
with the t(11;14) (P value = 0.0198), and a lower 
occurrence of hyperdiploidy among DIS3- mutated cases 
(P value = 0.025). Conversely, we were unable to find any 
association with 17p deletion, 1q gain or 1p loss (Table 2). 
Although not significantly associated with 13q14 deletion, 
DIS3 mutations occurred in several cases carrying 
this chromosomal alteration. Specifically, 19 of the 33 
(57.6%) DIS3-mutated patients harbored del(13q14). For 
eight of them, genome-wide DNA profiling data were 
also available [16, 17], indicating that in all but one case 
(PCL-019) the chromosomal deletion included the DIS3 
locus. Interestingly, VAFs around 100% were exclusively 
observed in a fraction of patients (10/19) with 13q 
deletion (and in all likelihood with heterozygous deletion 
of the DIS3 locus). In the other cases, i.e. the remaining 
del(13q14) samples (9/19) and all the 14 patients disomic 
for chromosome 13, the VAFs we found were indicative 
of mutations occurring in hemizygosis in tumor subclones 
or carried in heterozygosis either by all or by a fraction of 
myelomatous cells (Supplementary Figure S2).
Variants detected at very low allele frequencies 
included both missense and frameshift mutations; some 
of these low-level variants (i.e. D488N, F775L, R820W) 
were also carried at higher VAFs in other patients. 
Interestingly, substitutions at residues R780, D487 and 
D488 (demonstrated or suggested to be particularly 
detrimental for DIS3 protein function) were never 
observed at VAFs higher than 50%, neither in the present 
nor in previously published datasets [6, 7, 13].
Figure 1: Frequency of SNVs and in-frame deletions in DIS3 coding region in MM, including information from 
literature. In the lower part of the figure, a schematic diagram of the DIS3 gene is reported, based on exon-intron organization of the 
longer transcript variant, NM_014953.4. Exons are numbered under the boxes, filled with black in the coding region. Exons sequenced 
in this study (i.e., exons 1–4 and exons 10–18) encompass respectively the entire PIN (cd09862, amino acids 9–197) and RNB domain 
(pfam00773, amino acids 467–791), plus portions of the flanking regions, as indicated by the blue and red dashed lines connecting the 
diagram of the gene to the scheme of the DIS3 protein, in the upper part of the figure. Here, somatic mutations identified in the present series 
and reported in the main MM datasets [3, 4, 6, 7, 13] are depicted.
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Longitudinal analysis of DIS3 mutations
To gain further insight into the state of DIS3 
mutations longitudinally, we analyzed 19 patients for 
whom BM specimens were collected at two different 
timepoints: in particular, fourteen MM and two pPCL 
cases collected both at onset and at relapse; two MM 
patients at onset and at leukemic transformation, and 
one patient at early and relapsed leukemic phase of MM 
(Figure 2, Supplementary Table S3). Fifteen out of the 19 
cases displayed a wild type DIS3 status at both timepoints, 
while one patient (MM-281) carrying the R780K variant 
showed a quite constant VAF during disease course (36.8% 
mutated reads at diagnosis, and 47.56% at leukemic 
transformation). MM-004, wild type at onset, acquired a 
missense mutation affecting a fully conserved amino acid 
residue downstream the RNB domain and suggested to be 
of functional relevance (A827P); this SNV was detected 
in 97.1% of the sequencing reads at relapse. This patient 
showed two copies of chromosome 13 both at onset and 
at relapse, and also the other cytogenetic lesions remained 
stable during disease progression. A considerable increase 
in mutation burden was observed in MM-263, with R467Q 
mutation occurring in 31.1% of reads at onset and 81.9% 
at relapse (this case also carried a frameshift mutation at 
the same position with VAF = 5.93% at diagnosis, which 
disappeared at relapse). Finally, MM-340 carried three 
variants at onset (L48_A56del, A751D and R689Q at 
VAF of 54.86%, 45.71% and 2.20%, respectively), two of 
which (L48_A56del and A751D) remained stable while 
the third (R689Q) was no longer detectable at relapse. 
The disappearance of mutations at high allele frequency 
at onset was never observed in our cohort.
Expression of DIS3 variants
To verify whether the DIS3 mutations here 
detected were expressed at transcriptional level, we 
Table 2: Clinical and molecular characteristics of the 164 MM/PCL patients analyzed for DIS3 
mutations
Characteristic All patients (n = 164) DIS3 wild type (n = 131) DIS3-mutated (n = 33) P valuea
N % n % n %
MM 130 79 106 81 24 73
n.s.pPCL 24 15 18 14 6 18
sPCL 10 6 7 5 3 9
del (13q) 77 47 58 45 19 58
n.s.
chr 13 disomic 
patients 86 53 72 55 14 42
del (17p) 17 10.5 15 12 2 6
n.s.
17p disomic 
patients 145 89.5 114 88 31 94
1q gain 66 43 49 39 17 57
n.s.
1q disomic 
patients 89 57 76 61 13 43
1p loss 18 13 16 14 2 7
n.s.
1p disomic 
patients 123 87 97 86 26 93
IGH 
translocation 81 50 58 44 23 74 0.0046
no IGH 
translocation 81 50 73 56 8 26
hyperdiploid 49 33 45 37 4 14
0.0250
non-
hyperdiploid 101 67 77 63 24 86
aSignificance was assessed by Freeman-Halton extension of Fisher’s exact test for disease type, and by Fisher’s exact test 
for all other variables. n.s.: not significant.
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performed the deep sequencing of cDNA samples of the 
DIS3-mutated cases for whom biological material was 
available. In particular, 20 DIS3 variants were evaluated 
at transcriptional level (Figure 3A). Notably, all the 
variants detected at VAFs higher than 6% on genomic 
DNA were also identified at RNA level, while none of 
the four tested low-frequency genomic mutations (VAFs 
ranging from 1.95% to 5.96%) was detected on cDNA. 
Overall, as regards expressed variants, mutant allele 
frequencies detected at gene and transcript level showed a 
good correlation (Figure 3B). Notably, the aforementioned 
increase in mutation burden from diagnosis to relapse 
observed in MM-263 for the variant R467Q was 
accompanied by a doubling of the amount of expressed 
mutant allele.
Transcriptomic profile of DIS3-mutated patients
To identify transcriptional gene profiles related to 
DIS3 mutations, we investigated by microarray technology 
a large fraction of MM samples of the present series, 
including both DIS3-mutated and wild type patients. 
Assuming that alterations present in a very limited 
number of malignant plasma cells might not appreciably 
affect gene expression, we chose to set at 20% the lower 
VAF cut-off to perform supervised analyses. We thus 
compared 89 wild type and 13 mutated patients for DIS3. 
This analysis revealed that 119 genes (q-value < 0.1) 
(Supplementary Table S4) were differentially expressed 
between the two groups. Notably, all transcripts were 
up-regulated in mutated cases (28 of these genes emerged 
at q-value = 0 – Figure 4). Interestingly, 74 were protein-
coding genes, while one gene was of unknown type and 
44 were non-coding RNAs/pseudogenes. In particular, 
this latter class of modulated transcripts included 
nine antisense RNAs (ARHGAP5-AS1, C21orf119, 
DLGAP1-AS1, HEXA-AS1, ILF3-AS1, LOC645212, 
MATN1-AS1, TAPT1-AS1, and ZNRD1-AS1), seven 
pseudogenes (CATSPER2P1, FLJ37201, GNRHR2, 
GVINP1, HTATSF1P2, NUDT9P1, and PRORSD1P), six 
long intergenic non-protein-coding RNAs (FLJ30403, 
TP53TG1, LINC00167, LINC00173, LINC00528, and 
LOC100129726), five small nuclear RNAs (RNU11, 
RNU12, RNU4ATAC, RNU5D-1, and RNU5F-1), two 
microRNAs (MIR23A and MIR320A), one microRNA-
host gene (MIRLET7BHG), and a group mainly consisting 
of uncharacterized loci and open reading frames. We then 
explored whether these transcripts belonged to specific 
functional subgroups. Remarkably, a significant fraction 
of them was involved, like DIS3 itself, in single-stranded 
RNA binding function (namely, PAT2L, DHX58, DDX60 
and KHDRBS2; P value = 1.01E-04) (Table 3). Beyond 
this specific molecular function, several other up-regulated 
genes in DIS3-mutated patients are implicated in RNA 
physiology: in particular, PAN2, POP1, RBM45 and the 
aforementioned PATL2 and KHDRBS2 genes are involved 
in RNA metabolism; APOBEC3F and APOBEC4 encode 
RNA editing enzymes; whereas RNU11, RNU12 and 
RNU4ATAC are spliceosome subunits. Notably, DHX58, 
DDX60 and APOBEC3F genes, along with IFIT1, IFIT3, 
IFI6, and OASL, are part of interferon-mediated anti-viral 
response.
Figure 2: Changes of DIS3 mutational burden during disease progression. For patients found mutated at diagnosis and/or 
relapse, allele frequencies of variants reported in the legend are plotted at both timepoints.
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Figure 4: Heatmap of the 28 differentially expressed genes identified at q-value = 0 by SAM two-class analysis of  
102 MM patients stratified based on the presence of DIS3 mutations. In the heatmap, the color-scale bar represents the relative 
gene expression changes normalized by the standard deviation, and the color changes in each row represent gene expression level relative 
to the mean across the samples.
Figure 3: DIS3 mutations detected on genomic DNA and cDNA. A. Percentages of variant DIS3 sequencing reads identified 
by NGS analyses of genomic DNA and retrotranscribed total RNA. B. Correlation between VAFs detected on genomic DNA and cDNA.
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DISCUSSION
DIS3 belongs to the human exosome complex and 
is endowed with both exo- and endonucleolytic activities. 
DIS3 regulates the processing and abundance of all 
RNA species [18]. Recently, DIS3 gene has emerged as 
recurrently mutated in MM patients from initial whole-
genome (WGS) and exome (WES) sequencing studies 
[4, 6, 7, 13, 19]. To the best of our knowledge, this is 
the first study assessing the DIS3 mutational status by 
means of NGS technology in a large cohort of patients 
including different molecular subtypes and phases (also 
leukemic stages) of PC dyscrasias and comprehensively 
evaluating it in the context of other molecular features, 
and determining the transcriptional profiles and putative 
altered pathways in mutated MM patients.
DIS3 mutations were globally identified in 20.1% 
of patients: specifically, mutation prevalence was 18.5% 
in newly diagnosed MM patients, 25% in pPCL at 
onset, and 30% in sPCL. Interestingly, DIS3 mutation 
frequency seemed to be slightly higher in extramedullary 
phases (although this difference did not reach statistical 
significance, likely due to the relatively small size of pPCL 
and sPCL series). Notably, a WES study in a fraction of 
the pPCL patients of the present series identified DIS3 as 
one of the 14 statistically significant recurrently affected 
genes with potential driver role in the disease [20]. As 
regards the prevalence of DIS3 mutations identified here 
in representative MM cases at onset (18.5%), it was higher 
than the one reported for unselected patients’ cohorts in 
other studies [4, 6, 13]. Most likely, this could be due to 
the higher depth of coverage of our sequencing analysis, 
especially compared to that usually obtained in WGS 
and WES experiments. Compared to the lower frequency 
(11%) reported by Weißbach et al. [13], who used our 
same targeted resequencing approach, this difference 
could be due to the exclusion in that study of the variants 
with VAF lower than 8%. We obtained similar results as 
of Walker et al. (18%) [7], who exclusively analyzed IGH-
translocated patients. Indeed, also in the present series, 
DIS3 mutations were confirmed preferentially associated 
with IGH translocations and nonhyperdiploid status.
Of the two functional domains investigated in 
this study, the RNB domain was slightly more densely 
affected by mutations. The mutations of the RNB domain 
initially identified in MM by Chapman et al. [4] interfere 
with DIS3 ribonucleolytic activity [10]. This functional 
effect could be envisaged also for many of the mutations 
identified by us, based on the bioinformatics predictions 
and the pattern of differential expression between DIS3-
mutated and wild type MM cases emerged from the gene 
expression profiling of our cohort. DIS3-mutated MM 
Table 3: Selected significantly enriched gene ontology terms in the DIS3 mutation-associated gene 
signature (q-value < 0.05, Benjamini Hochberg correction)
Category Name q-value Genes
GO: Molecular Function single-stranded RNA binding 2.01E-02 PATL2, DHX58, DDX60, KHDRBS2
GO: Biological Process
positive regulation of MDA-5 
signaling pathway 3.32E-02 DHX58, DDX60
GO: Biological Process
regulation of MDA-5 
signaling pathway 3.32E-02 DHX58, DDX60
GO: Biological Process
positive regulation of RIG-I 
signaling pathway 3.32E-02 DHX58, DDX60
GO: Biological Process defense response to virus 3.32E-02
DHX58, DDX60, IFIT1, IFIT3, APOBEC3F, 
OASL
GO: Biological Process
cellular response to type I 
interferon 3.32E-02 IFIT1, IFIT3, OASL, IFI6
GO: Biological Process
type I interferon signaling 
pathway 3.32E-02 IFIT1, IFIT3, OASL, IFI6
GO: Biological Process MDA-5 signaling pathway 3.32E-02 DHX58, DDX60
GO: Biological Process response to type I interferon 3.32E-02 IFIT1, IFIT3, OASL, IFI6
GO: Biological Process
regulation of defense 
response to virus
3.76E-02 DHX58, DDX60, IFIT1, APOBEC3F
Pathway (REACTOME) Interferon alpha/beta signaling 1.01E-04 IFIT1, IFIT3, OASL, IFI6
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samples, in fact, displayed the up-regulation of several 
transcripts, including genes involved in RNA interactions 
and many non-coding transcripts. The finding that all the 
involved transcripts were over-expressed in DIS3-mutated 
patients reflects what reported by several studies analyzing 
the transcriptional output resulting from the mutation or 
depletion of exosome subunits in other species, and is 
consistent with the RNA degradative activities ascribed to 
the exosome [21–23]. Also the nature of these transcripts, 
in particular for non-protein-coding RNAs, could be 
compatible with the accumulation of physiological 
exosome substrates due to the loss of function of DIS3. 
In fact, we could notice some similarities between the 
transcriptional profile characterizing our DIS3-mutated 
MM patients and the genome-wide atlas of Arabidopsis 
thaliana exosome targets presented by Chekanova et al., 
including hundreds of non-coding RNAs, most of which 
have not been previously described [21]. Among those 
targets, Chekanova et al. reported upstream non-coding 
transcripts (UNTs), rRNA precursors, snoRNAs, snRNAs, 
pseudogenes, pri-miRNAs, and transcripts having neither 
protein-coding potential nor predicted function [21]. 
Interestingly, as reported by Tomecki et al., Northern blot 
analyses in HEK293 cells expressing MM-associated DIS3 
mutations (such as R780K) revealed the accumulation of 
the majority of analyzed exosome substrates, including 
5.8S processing intermediates, tRNAs, RNA polymerase 
III transcripts and PROMPTs (i.e. PROMoter uPstream 
Transcripts), these latters generated 0.5 to 2.5 kb upstream 
of active transcription start sites and rapidly turned over 
by the RNA exosome [10]. The accumulation of similar 
nuclear non-coding RNAs (such as cryptic unstable 
transcripts, CUTs) when MM DIS3 mutations were 
expressed in yeast led the same Authors to speculate 
that the level of ‘transcriptional noise’ is probably much 
higher in the nucleus of the cells producing DIS3-mutated 
variants. Concerning the up-regulation of genes involved 
in interferon-mediated anti-viral response observed in 
the DIS3-mutated MM patients of our cohort, a potential 
parallel might be suggested between the induction of anti-
viral transcriptional response found associated with DIS3 
mutations in our study and the recently reported evidence 
that SKIV2L, the helicase component of the RNA 
exosome, is involved in the degradation of endogenous 
RNAs that might inappropriately trigger the RLRs (RIG-
I-like receptors), which are the cytosolic sensors of viral 
RNAs that initiate host defense, including secretion of 
type I interferons. Thus, SKIV2L prevents aberrant innate 
immune responses; remarkably, humans with deficiency 
in SKIV2L have a type I interferon signature in their 
peripheral blood [24].
The gene expression patterns observed in our study 
suggested that identified mutations here are actually 
expressed, as directly assessed by cDNA sequencing of 
DIS3-mutated patients showing comparable mutation 
burdens at gene and transcript levels. Overall, these data 
demonstrate the ultimate significance of the DIS3 gene 
mutations, differently from what has been suggested for 
the majority of the genetic changes detected by genome-
wide approaches in MM, which are found in genes that 
have low or no detectable biological expression [25]. In 
this regard, it is also worth noting that substitutions at 
residues R780, D487 and D488 (demonstrated or supposed 
to be particularly detrimental for protein function) were 
never observed at genomic VAFs above 50%, neither in 
the present nor in previously published datasets [6, 7, 13], 
suggesting that the exclusive presence of such DIS3 
mutant forms in the absence of a DIS3 wild type protein 
might have deleterious cellular effects. In general, the lack 
of a DIS3 wild type allele in mutated cases was uniquely 
observed in some 13q14-deleted MM patients carrying 
other types of variants.
Furthermore, looking at DIS3 mutations in 
longitudinally analyzed patients (i.e. sampled at diagnosis 
and relapse), we observed a similar scenario to that 
described by Bolli et al. [3] for other known driver 
myeloma genes, i.e. the occurrence of clonal variants 
at both timepoints or the acquisition/clonal expansion 
of variants at the later timepoint, consistently with an 
expected positive selection for the subclones harboring 
them. Of note, the disappearance at relapse of variants 
found at diagnosis at low allele frequency was only 
observed in patients carrying additional stable/clonally 
expanding mutations. The limited sample size and the 
different treatment regimens to which the patients were 
subjected do not allow making assumptions on the 
possible impact of specific therapies on the chances of 
survival of DIS3-mutated subclones.
The clinical implications of DIS3 mutations 
in MM remain to be elucidated. Recently, Weißbach 
et al. [13] reported that the occurrence of DIS3 mutations 
in minor subclones was significantly associated with a 
weaker chemotherapy response as compared to the DIS3 
mutations in major subclones, while globally there was 
only a slight trend towards shorter median overall survival 
for DIS3-mutated MM patients as compared to DIS3 wild 
type ones. In our series, we had the possibility to evaluate 
the prognostic impact of DIS3 mutations in the group 
of pPCLs included in a prospective multicenter clinical 
trial [26] for whom a 2.8-month follow-up was available, 
observing no significant association with survival or 
response rate (data not shown).
In conclusion, our data confirm and extend the 
evidence that DIS3 mutations are recurrent in MM, 
suggesting an even greater involvement of DIS3 
alterations in more advanced stages of PC dyscrasias, 
and highlighting some instances of increase of DIS3 
mutation burden during disease progression. Although 
its role in the pathogenesis of the disease remains to be 
further elucidated, DIS3 is considered a potential tumor 
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suppressor in MM. This suggestion is based on the loss 
of enzymatic activity caused by the MM-associated DIS3 
mutations that have been functionally characterized [10]; 
the loss of heterozigosity/disruption (as also elucidated in 
our study) often involving DIS3 due to the combination 
of gene mutations and chromosome 13 deletion; and the 
increased translation of critical oncogenes observed as 
one of the biological outcomes of DIS3 inactivation [14]. 
Importantly, the transcriptional phenotype observed here 
in DIS3-mutated MM patients could be consistent with 
an impaired function of the RNA exosome complex, thus 
further supporting the pathological role of DIS3 alterations 
in the disease.
MATERIALS AND METHODS
Patients and cell lines
After the patients had given their informed consent 
in accordance with institutional guidelines (clearance 
from Ethic Committee, Fondazione Ospedale Maggiore 
di Milano, Italy), pathological BM specimens were 
obtained during standard diagnostic procedures from 130 
newly diagnosed MM patients, 8 pPCL cases at onset, 
and 10 sPCLs, admitted from July 2001 to April 2014. 
Additional 16 pPCL patients were included in a multicenter 
clinical trial (RV-PCL-PI-350, EudraCT N°2008-003246-
28) [26]. Seventy-seven patients were males; median age 
was 66 years (range: 42–85). The diagnosis of MM and PCL 
was made according to the previously described criteria 
[2, 27]. Ninety-nine patients had an immunoglobulin (Ig) 
G protein monoclonal component; 34 IgA; one IgG/IgA; 
and one IgM protein; 99 cases had the light chain κ; 62 λ; 
and two λ+κ. Twenty-five MM cases were in stage IA, 57 
in IIA/B and 48 in IIIA/B, according to Durie and Salmon 
criteria [28]. Many of the patients included in this study 
have been described in our previous reports [29, 30].
HMCLs investigated in this study were the 
following: NCI-H929, OPM2, JJN3, KMS-12, KMS-28, 
KMS-34, KMS-18, KMS-11, KMS-26, AMO1, RPMI 
8226, DELTA-47, SK-MM-1, UTMC-2, MM.1S, U266, 
CMA-03 and CMA-03/06, LP-1, KMS-27. With the 
exception of DELTA-47, UTMC-2 and MM.1S, all the 
others have been previously described and reported by us 
[31, 32].
Sample preparation and molecular analyses
The BM specimens were collected from patients at the 
time of diagnosis; 19 cases were re-sampled at relapse/MM 
leukemic transformation (median time interval between 
the two samplings: 30 months). PCs were purified 
(≥ 90% in all cases) using CD138 immunomagnetic 
microbeads as previously described [33, 34]. All cases 
were characterized by fluorescence in situ hybridization 
(FISH) for the main genomic aberrations (namely, IGH 
translocations, hyperdiploidy, del(13q), del(17p), del(1p) and 
1q gain) [16] (Supplementary Table S5), and by NGS for the 
mutational status of BRAF, NRAS and KRAS genes [8].
Mutation analyses
NGS of DIS3 exons 1–4 (PIN domain) and exons 10–
18 (RNB domain) (RefSeq NM_014953.4, representing 
the longer transcript encoding the longest protein isoform) 
was performed on genomic DNA using the Genome 
Sequencer Junior instrument (Roche-454 Life Sciences, 
Penzberg, Germany), as previously described [35]. 
Further details on primer sequences and sequencing 
protocol are available in the Supplementary Materials 
and Methods and Supplementary Table S6 and S7. 
The obtained sequencing reads were mapped to the DIS3 
human reference sequence (RefSeq NC_000013.10) 
and analyzed by the Amplicon Variant Analyzer (AVA) 
software version 3.0 (454 Life Sciences) to establish the 
variant allele frequency.
The presence of each obtained non-synonymous 
variant was verified in an independent PCR product by 
conventional sequencing whenever the sensitivity of the 
Sanger method was consistent with the VAF. NGS analysis 
was repeated in case of mutations detected in less than 
10% of sequencing reads. To exclude germline variants, 
we sequenced the matched normal DNA, when available, 
or consulted the NCBI Human dbSNP Database (Build 
142, http://www.ncbi.nlm.nih.gov/snp). The occurrence 
of DIS3 variants was also verified at transcriptional level 
(see Supplementary Materials and Methods).
Additional information about the functional 
relevance of the detected SNVs was obtained using 
five bioinformatics tools which calculate possible 
impact of amino acid substitutions on the structure 
and function of human proteins using straightforward 
physical and evolutionary comparative considerations. 
The functional predictors used were Polyphen2 
(http://genetics.bwh.harvard.edu/pph2/), Mutation Taster 
(http://www.mutationtaster.org/), Mutation Assessor (http://
mutationassessor.org/), SIFT (http://sift.jcvi.org/) and LRT 
(http://www.genetics.wustl.edu/jflab/lrt_query. html).
Gene expression profiling
For gene expression profiling (GEP), samples 
were profiled on the GeneChip Human Gene 1.0 ST 
array (Affymetrix, Santa Clara, CA, USA), as previously 
described [30]. Supervised analyses were performed 
using Significant Analysis of Microarrays software 
(SAM version 4.00; Excel front-end publicly available at 
http://www-stat.stanford.edu/tibs/SAM/index. html) [36]. 
The functional annotation analysis of selected gene lists 
was performed by means of DAVID 6.7 tool (http://david.
abcc.ncifcrf.gov/) and the ToppFun option of ToppGene 
Suite (https://toppgene.cchmc.org/), using the default 
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parameters. Details on GEP data generation and analysis 
are included in the Supplementary Materials and Methods. 
The GEP data have been deposited in the NCBI Gene 
Expression Omnibus database (GEO; http//www.ncbi.nlm 
.nih.gov/geo; accession No. GSE66293).
Statistical analyses
All contingency analyses were performed by two-
sided Fisher’s exact test (P value < 0.05).
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